240 related articles for article (PubMed ID: 27299751)
21. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment.
Bonnet S; Hartl D; Leboulleux S; Baudin E; Lumbroso JD; Al Ghuzlan A; Chami L; Schlumberger M; Travagli JP
J Clin Endocrinol Metab; 2009 Apr; 94(4):1162-7. PubMed ID: 19116234
[TBL] [Abstract][Full Text] [Related]
22. Is radioiodine ablation necessary for patients with low-risk papillary thyroid carcinoma and tumor >4 cm?
Rosario PW
Eur J Surg Oncol; 2017 Sep; 43(9):1802-1803. PubMed ID: 28743373
[No Abstract] [Full Text] [Related]
23. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
[TBL] [Abstract][Full Text] [Related]
25. [Postoperative follow-up in differentiated carcinoma of the thyroid gland].
Pandolfi C
Minerva Med; 1986 Jun; 77(27):1317-9. PubMed ID: 3725155
[TBL] [Abstract][Full Text] [Related]
26. Thyroglobulin measurements in the follow-up of patients with differentiated thyroid carcinoma: comparison with quantitative radioactive iodine uptake measurements and total body scans.
Bolk JH; Bussemaker JK; Nieuwenhuijzen Kruseman AC; De Vijlder JJ; Goslings BM
Neth J Med; 1985; 28(9):340-6. PubMed ID: 4047268
[No Abstract] [Full Text] [Related]
27. [Limited radical approach in differentiated thyroid gland cancers. A prospective study of 107 patients].
Engel U; Kucharski A; Zornig C
Chirurg; 1994 Dec; 65(12):1095-8; discussion 1098-9. PubMed ID: 7851141
[TBL] [Abstract][Full Text] [Related]
28. Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma.
Tamilia M; Al-Kahtani N; Rochon L; Hier MP; Payne RJ; Holcroft CA; Black MJ
Nucl Med Commun; 2011 Mar; 32(3):212-20. PubMed ID: 21191314
[TBL] [Abstract][Full Text] [Related]
29. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
30. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin.
Westbury C; Vini L; Fisher C; Harmer C
Thyroid; 2000 Feb; 10(2):171-6. PubMed ID: 10718555
[TBL] [Abstract][Full Text] [Related]
31. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
32. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
[TBL] [Abstract][Full Text] [Related]
34. Lymph node status influences follow-up thyroglobulin levels in papillary thyroid cancer.
Low TH; Delbridge L; Sidhu S; Learoyd D; Robinson B; Roach P; Sywak M
Ann Surg Oncol; 2008 Oct; 15(10):2827-32. PubMed ID: 18636294
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ
J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
[TBL] [Abstract][Full Text] [Related]
36. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
37. [Thyroid microcarcinoma: experience and management in private clinic].
Friguglietti CU; Kulcsar MA
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):774-82. PubMed ID: 17891241
[TBL] [Abstract][Full Text] [Related]
38. [Use of serum thyroglobulin determination in the follow-up of differentiated carcinomas of the thyroid].
Secades Ariz I; Pérez Piqueras JL; Labanda Tejedor P; Cordero Peinado J
An Med Interna; 1988 Sep; 5(9):439-43. PubMed ID: 2856622
[No Abstract] [Full Text] [Related]
39. Outcome of primary papillary carcinoma of thyroglossal duct cyst with local infiltration to soft tissues and uninvolved thyroid.
Basu S; Shet T; Borges AM
Indian J Cancer; 2009; 46(2):169-70. PubMed ID: 19346653
[No Abstract] [Full Text] [Related]
40. Current perspectives on papillary carcinoma of the thyroid gland.
Chiu MK; Sherry RM; Wei JP
J Med Assoc Ga; 1992 Aug; 81(8):442-4. PubMed ID: 1512532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
